Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to change the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device. The Company is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression.
Revenue (Q1, 2018)
Gross profit (Q1, 2018)
Gross profit margin (Q1, 2018), %
EBIT (Q1, 2018)
Market capitalization (18-Jul-2018)
Closing share price (18-Jul-2018)
Glaukos has 49 number of Facebook Likes. The number of likes has decrease 0.4% month over month and decrease 5.2% quarter over quarter